Macrophage Checkpoint Nanoimmunotherapy Has the Potential to Reduce Malignant Progression in Bioengineered <i>In Vitro</i> Models of Ovarian Cancer.

VandenHeuvel, Sabrina N; Chau, Eric; Mohapatra, Arpita; Dabbiru, Sameera; Roy, Sanjana; O'Connell, Cailin; Kamat, Aparna; Godin, Biana; Raghavan, Shreya A

Macrophage Checkpoint Nanoimmunotherapy Has the Potential to Reduce Malignant Progression in Bioengineered In Vitro Models of Ovarian Cancer.

VandenHeuvel, Sabrina N; Chau, Eric; Mohapatra, Arpita; Dabbiru, Sameera; Roy, Sanjana; O'Connell, Cailin; Kamat, Aparna; Godin, Biana; Raghavan, Shreya A.

Afiliação

VandenHeuvel SN; Department of Biomedical Engineering, Texas A&M University, 3120 TAMU, College Station, Texas 77843, United States.
Chau E; Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, Texas 77030, United States.
Mohapatra A; Department of Biomedical Engineering, Texas A&M University, 3120 TAMU, College Station, Texas 77843, United States.
Dabbiru S; Department of Biomedical Engineering, Texas A&M University, 3120 TAMU, College Station, Texas 77843, United States.
Roy S; Department of Biomedical Engineering, Texas A&M University, 3120 TAMU, College Station, Texas 77843, United States.
O'Connell C; Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, Texas 77030, United States.
Kamat A; School of Engineering Medicine, Texas A&M University, 1020 Holcombe Boulevard, Houston, Texas 77030, United States.
Godin B; Division of Gynecologic Oncology, Houston Methodist Hospital, 6550 Fannin Street, Houston, Texas 77030, United States.
Raghavan SA; Department of Obstetrics and Gynecology, Houston Methodist Hospital, 6550 Fannin Street, Houston, Texas 77030, United States.